Drugs / Dalpicicilip
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06509997 | Aug 2024 → Dec 2026 expected | head and neck squamous cell carcinoma | Lei Liu | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dalpicicilip | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06509997 ↗ |
| Action | Inhibit | “CDK4/6 inhibitor” NCT06509997 ↗ |
| Route | Oral | “Dalpicicilip, taking orally” NCT06509997 ↗ |
| Target | CDK4 | “CDK4/6 inhibitor” NCT06509997 ↗ |